{"id":"aprotinin","rwe":[],"tags":[{"label":"Antifibrinolytic Agent","category":"class"},{"label":"Biologic","category":"modality"},{"label":"Plasminogen","category":"target"},{"label":"PLG","category":"gene"},{"label":"KLKB1","category":"gene"},{"label":"B02AB01","category":"atc"},{"label":"Active","category":"status"},{"label":"Hemorrhage","category":"indication"},{"label":"Bayer Hlthcare","category":"company"},{"label":"Approved 1990s","category":"decade"},{"label":"Coagulants","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Hematologic Agents","category":"pharmacology"},{"label":"Hemostatics","category":"pharmacology"},{"label":"Protease Inhibitors","category":"pharmacology"},{"label":"Serine Proteinase Inhibitors","category":"pharmacology"},{"label":"Trypsin Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":303.453,"date":"","count":86,"signal":"Product use in unapproved indication","source":"DrugCentral FAERS","actionTaken":"Reported 86 times (LLR=303)"},{"llr":172.224,"date":"","count":80,"signal":"Off label use","source":"DrugCentral FAERS","actionTaken":"Reported 80 times (LLR=172)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"company":"Bayer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=APROTININ","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:31:04.816734+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:31:12.333442+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=APROTININ","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:31:13.271156+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Plasma kallikrein inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:31:13.864447+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201619/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:31:13.746364+00:00"}},"allNames":"trasylol","offLabel":[],"synonyms":["aprotinin","trasylol"],"timeline":[{"date":"1993-12-29","type":"positive","source":"DrugCentral","milestone":"FDA approval (Bayer Hlthcare)"}],"aiSummary":"Trasylol (Aprotinin) is a small molecule antifibrinolytic agent developed by Bayer Healthcare, targeting plasminogen to prevent excessive bleeding. It was FDA-approved in 1993 for the treatment of hemorrhage. As a patented product, its commercial status is proprietary to Bayer Healthcare. Key safety considerations include potential allergic reactions and interactions with other medications. Trasylol works by inhibiting the activity of plasminogen, a protein involved in the breakdown of blood clots.","brandName":"Trasylol","ecosystem":[{"indication":"Hemorrhage","otherDrugs":[{"name":"menadiol sodium diphosphate","slug":"menadiol-sodium-diphosphate","company":"Lilly"}],"globalPrevalence":null}],"mechanism":{"target":"Plasminogen","novelty":"Follow-on","targets":[{"gene":"PLG","source":"DrugCentral","target":"Plasminogen","protein":"Plasminogen"},{"gene":"KLKB1","source":"DrugCentral","target":"Plasma kallikrein","protein":"Plasma kallikrein"}],"modality":"Small Molecule","drugClass":"Antifibrinolytic Agent","explanation":"","oneSentence":"","technicalDetail":"Trasylol is a serine protease inhibitor that targets plasminogen, kallikrein, and trypsin, thereby inhibiting the fibrinolytic cascade and preventing excessive bleeding."},"commercial":{"launchDate":"1993","_launchSource":"DrugCentral (FDA 1993-12-29, BAYER HLTHCARE)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4839","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=APROTININ","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=APROTININ","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:48:58.598219","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:31:15.660874+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"alteplase","drugSlug":"alteplase","fdaApproval":"1996-06-18","relationship":"same-target"},{"drugName":"aminocaproic acid","drugSlug":"aminocaproic-acid","fdaApproval":"1964-06-03","genericCount":21,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"berotralstat","drugSlug":"berotralstat","fdaApproval":"2020-12-03","patentExpiry":"Sep 9, 2035","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"dabigatran etexilate","drugSlug":"dabigatran-etexilate","fdaApproval":"2010-10-19","patentExpiry":"Mar 7, 2026","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"pentamidine","drugSlug":"pentamidine","fdaApproval":"1984-10-16","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"reteplase","drugSlug":"reteplase","fdaApproval":"1996-10-30","relationship":"same-target"},{"drugName":"telaprevir","drugSlug":"telaprevir","fdaApproval":"2011-05-23","patentExpiry":"May 30, 2028","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"tenecteplase","drugSlug":"tenecteplase","fdaApproval":"2000-06-02","relationship":"same-target"},{"drugName":"tranexamic acid","drugSlug":"tranexamic-acid","fdaApproval":"1986-12-30","genericCount":26,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"urokinase","drugSlug":"urokinase","fdaApproval":"","relationship":"same-target"}],"genericName":"aprotinin","indications":{"approved":[{"name":"Hemorrhage","source":"DrugCentral","snomedId":50960005,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"alteplase","brandName":"alteplase","genericName":"alteplase","approvalYear":"1996","relationship":"same-target"},{"drugId":"aminocaproic-acid","brandName":"aminocaproic acid","genericName":"aminocaproic acid","approvalYear":"1964","relationship":"same-target"},{"drugId":"berotralstat","brandName":"berotralstat","genericName":"berotralstat","approvalYear":"2020","relationship":"same-target"},{"drugId":"dabigatran-etexilate","brandName":"dabigatran etexilate","genericName":"dabigatran etexilate","approvalYear":"2010","relationship":"same-target"},{"drugId":"pentamidine","brandName":"pentamidine","genericName":"pentamidine","approvalYear":"1984","relationship":"same-target"},{"drugId":"reteplase","brandName":"reteplase","genericName":"reteplase","approvalYear":"1996","relationship":"same-target"},{"drugId":"telaprevir","brandName":"telaprevir","genericName":"telaprevir","approvalYear":"2011","relationship":"same-target"},{"drugId":"tenecteplase","brandName":"tenecteplase","genericName":"tenecteplase","approvalYear":"2000","relationship":"same-target"},{"drugId":"tranexamic-acid","brandName":"tranexamic acid","genericName":"tranexamic acid","approvalYear":"1986","relationship":"same-target"},{"drugId":"urokinase","brandName":"urokinase","genericName":"urokinase","approvalYear":"","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT03189355","phase":"NA","title":"Expression of Protein Tyrosine Phosphatase 1B (PTP1B) and Body Composition Modification in Patients With Septic Shock","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2017-01-09","conditions":["Septic Shock"],"enrollment":52,"completionDate":"2018-10-14"},{"nctId":"NCT07337707","phase":"NA","title":"New Microbiota-endocrine Axis in Fructose Malabsorption-caused Visceral Hypersensitivity in Irritable Bowel Syndrome.","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2026-02","conditions":["Irritable Bowel Syndrome (IBS)"],"enrollment":60,"completionDate":"2027-08"},{"nctId":"NCT07317050","phase":"PHASE3","title":"Clinical Trial With Aprotinin in the Acute Respiratory Distress Syndrome Treatment","status":"NOT_YET_RECRUITING","sponsor":"Fundacion del Hospital Nacional de Paraplejicos para la Investigacion y la Integracion","startDate":"2026-03-01","conditions":["Acute Respiratory Distress Syndrome (ARDS)"],"enrollment":156,"completionDate":"2030-03-01"},{"nctId":"NCT04602689","phase":"NA","title":"Fibrin Glue After ESD for High Risk Patients of Bleeding","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2020-10-30","conditions":["Early Gastric Cancer","Gastric Adenoma"],"enrollment":134,"completionDate":"2022-07-14"},{"nctId":"NCT06328049","phase":"PHASE2","title":"A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC","status":"RECRUITING","sponsor":"Taixing People's Hospital","startDate":"2023-08-10","conditions":["NSCLC"],"enrollment":30,"completionDate":"2025-08-10"},{"nctId":"NCT05490940","phase":"NA","title":"Sensory Recovery of Digital Nerves After Microsurgical Epineural Neurorrhaphy Alone or in Combination With Tisseel - RET","status":"UNKNOWN","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-03-01","conditions":["Digital Nerve Injuries"],"enrollment":74,"completionDate":"2025-12-31"},{"nctId":"NCT05645198","phase":"PHASE4","title":"The Effect of Carboxymetyl Starch (Oozfix) on Preventing Postoperative Complication After Gastrectomy","status":"UNKNOWN","sponsor":"Bucheon St. Mary's Hospital","startDate":"2022-10-26","conditions":["Stomach Neoplasm"],"enrollment":180,"completionDate":"2025-01-31"},{"nctId":"NCT04804345","phase":"","title":"AProtinin Versus Tranexamic Acid in Cardiac Surgery Patients With High-risk for Excessive Bleeding","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2021-03-31","conditions":["Cardiac Surgery","Cardiopulmonary Bypass","High Risk Bleeding"],"enrollment":693,"completionDate":"2021-08-31"},{"nctId":"NCT04527133","phase":"NA","title":"An Open Non-comparative Study of the Efficacy and Safety of Aprotinin in Patients Hospitalized With COVID-19","status":"UNKNOWN","sponsor":"Aviron LLC","startDate":"2020-06-11","conditions":["COVID-19"],"enrollment":30,"completionDate":"2020-08-31"},{"nctId":"NCT00327379","phase":"PHASE3","title":"Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Elective Spinal Fusion Surgery","status":"TERMINATED","sponsor":"Bayer","startDate":"2006-02-27","conditions":["Blood Loss, Surgical","Postoperative Hemorrhage"],"enrollment":54,"completionDate":"2007-03-01"},{"nctId":"NCT00405093","phase":"","title":"Aprotinin Use and Renal Outcome in Hypothermic Bypass and Circulatory Arrest for Surgical Repair of Thoracic Aorta.","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2006-07","conditions":["Circulatory Arrest"],"enrollment":1250,"completionDate":"2013-05"},{"nctId":"NCT01550406","phase":"PHASE4","title":"Use of Polyethylene Glycolic Acid or Tachocomb to Prevent Pancreatic Fistula Following Distal Pancreatectomy","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2011-11","conditions":["Pancreatic Fistula"],"enrollment":150,"completionDate":""},{"nctId":"NCT00617955","phase":"","title":"Effects of Aprotinin During Cardiac Surgery/Long Term Death Rates","status":"COMPLETED","sponsor":"State University of New York - Upstate Medical University","startDate":"2007-09","conditions":["Cardiac Surgery"],"enrollment":462,"completionDate":"2009-06"},{"nctId":"NCT02545153","phase":"PHASE2","title":"Fibrin Sealant for Cholangiotomy Closure Study","status":"UNKNOWN","sponsor":"Lasarettet i Enköping","startDate":"2009-01","conditions":["Common Bile Duct Gall Stones","Infection","Bile Leak"],"enrollment":200,"completionDate":"2016-12"},{"nctId":"NCT01436734","phase":"NA","title":"Role of Aprotinin in Glucagon Degradation, Measurement by Radioimmunoactive Method (RIA) I125","status":"COMPLETED","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2011-07","conditions":["Hyperglucagonemia"],"enrollment":5,"completionDate":"2013-05"},{"nctId":"NCT00131040","phase":"NA","title":"Investigation of Leukocyte Trafficking Into Skin Blisters During Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2003-01","conditions":["Ischemic Heart Disease","Angina Pectoris"],"enrollment":24,"completionDate":"2005-06"},{"nctId":"NCT00668031","phase":"PHASE3","title":"Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement","status":"COMPLETED","sponsor":"Bayer","startDate":"2005-02","conditions":["Blood Loss, Surgical"],"enrollment":359,"completionDate":"2006-01"},{"nctId":"NCT00306150","phase":"PHASE3","title":"Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients Undergoing Radical or Total Cystectomy","status":"TERMINATED","sponsor":"Bayer","startDate":"2005-12","conditions":["Blood Loss, Surgical","Postoperative Hemorrhage"],"enrollment":57,"completionDate":"2007-03"},{"nctId":"NCT00306137","phase":"PHASE3","title":"Study to Investigate the Effect of Aprotinin of Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung or Esophageal Cancer","status":"TERMINATED","sponsor":"Bayer","startDate":"2005-12","conditions":["Blood Loss, Surgical"],"enrollment":104,"completionDate":"2007-03"},{"nctId":"NCT00611845","phase":"","title":"Aprotinin US Special Access Protocol","status":"NO_LONGER_AVAILABLE","sponsor":"Bayer","startDate":"","conditions":["Postoperative Hemorrhage"],"enrollment":0,"completionDate":""},{"nctId":"NCT00681824","phase":"PHASE2","title":"Fibrin Sealant for the Sealing of Dura Sutures","status":"COMPLETED","sponsor":"Baxter Healthcare Corporation","startDate":"2008-05","conditions":["Pathological Processes in the Posterior Fossa","Dura Defects"],"enrollment":95,"completionDate":"2010-03"},{"nctId":"NCT01244425","phase":"PHASE2","title":"Fibrin Sealant VH S/D 500 S-apr in Hepatic Resection","status":"COMPLETED","sponsor":"Baxter Healthcare Corporation","startDate":"2010-11","conditions":["Bleeding (Oozing) in Hepatic Resection"],"enrollment":70,"completionDate":"2011-07"},{"nctId":"NCT00892957","phase":"PHASE3","title":"FS VH S/D 500 S-apr in Vascular Surgery","status":"COMPLETED","sponsor":"Baxter Healthcare Corporation","startDate":"2009-07","conditions":["Hemostasis in Participants Receiving Peripheral Vascular Expanded Polytetrafluoroethylene (ePTFE) Graft Prostheses"],"enrollment":176,"completionDate":"2010-11"},{"nctId":"NCT00576420","phase":"PHASE2","title":"Fibrin Sealant Vascular Surgery Study","status":"COMPLETED","sponsor":"Baxter Healthcare Corporation","startDate":"2007-12","conditions":["Adjunct to Hemostasis in Vascular Surgery (Synthetic Vascular Grafts)"],"enrollment":101,"completionDate":"2008-12"},{"nctId":"NCT00708071","phase":"PHASE2","title":"Efficacy and Safety Study of Fibrin Sealant With 4 IU/mL Thrombin, Vapor Heated, Solvent Detergent Treated (FS VH S/D 4) in Face-Lift Procedures","status":"COMPLETED","sponsor":"Baxter Healthcare Corporation","startDate":"2008-06","conditions":["Facial Rhytidectomy (Face-lift)"],"enrollment":45,"completionDate":"2008-09"},{"nctId":"NCT00290836","phase":"PHASE4","title":"Assess Efficacy and Safety of TachoComb H vs. Standard Surgical Treatment (i.e. Suturing) in Patients Undergoing Prostatectomy (TC-017-AU)","status":"COMPLETED","sponsor":"Nycomed","startDate":"2004-05","conditions":["Control of Local Bleeding in Patients Undergoing Prostatectomy."],"enrollment":120,"completionDate":"2007-08"},{"nctId":"NCT00469742","phase":"","title":"Aprotinin in Neonates Undergoing Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"Children's Healthcare of Atlanta","startDate":"2007-04","conditions":["Cardiopulmonary Bypass","Congenital Defects","Hemostasis"],"enrollment":290,"completionDate":"2008-12"},{"nctId":"NCT00257751","phase":"NA","title":"Different Regimen of Aprotinine(Trasylol) Administration in Patients Receiving Antiplatelet Therapy With Clopidogrel (Plavix)","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2004-03","conditions":["Coronary Artery Disease"],"enrollment":400,"completionDate":"2007-11"},{"nctId":"NCT00357851","phase":"PHASE1","title":"Can Aprotinin Reduce Pancreatitis After Scoliosis Surgery","status":"COMPLETED","sponsor":"Nemours Children's Clinic","startDate":"2005-03","conditions":["Pancreatitis"],"enrollment":120,"completionDate":""},{"nctId":"NCT00354900","phase":"PHASE1","title":"Phase I Study of Aprotinin in Advanced Breast Cancer","status":"TERMINATED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2006-07","conditions":["Metastatic Breast Cancer"],"enrollment":18,"completionDate":"2007-04"},{"nctId":"NCT00909649","phase":"NA","title":"Influence of Fibrin Glue on Seroma Formation After Modified Radical Mastectomy","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2005-01","conditions":["Breast Cancer"],"enrollment":50,"completionDate":"2007-06"},{"nctId":"NCT00396760","phase":"PHASE3","title":"Comparison of Aprotinin and Tranexamic Acid in Routine Cardiac Surgery","status":"UNKNOWN","sponsor":"German Heart Center","startDate":"2005-01","conditions":["Bleeding and Cardiac Surgery","Allogeneic Blood Transfusion","Aortic Valve Replacement","Coronary Artery Bypass Graft Surgery"],"enrollment":220,"completionDate":"2006-07"},{"nctId":"NCT00395369","phase":"NA","title":"Effect of Intraoperative Aprotinin Administration on Post Cardiac Surgery Optic Nerve and Retinal Thickness.","status":"UNKNOWN","sponsor":"Soroka University Medical Center","startDate":"2007-12","conditions":["Cardiac Surgery"],"enrollment":30,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000148360","MMSL":"1439","NDDF":"003455","UNII":"04XPW8C0FL","VUID":"4020852","VANDF":"4020852","INN_ID":"2481","RXNORM":"1056","UMLSCUI":"C0003641","chemblId":"CHEMBL1201619","ChEMBL_ID":"CHEMBL1201619","DRUGBANK_ID":"DB06692","PUBCHEM_CID":"16130295","SNOMEDCT_US":"109008002","IUPHAR_LIGAND_ID":"6570","MESH_DESCRIPTOR_UI":"D007611"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1993-","companyName":"Bayer","relationship":"Original Developer"}],"publicationCount":4483,"therapeuticAreas":["Hematology"],"atcClassification":{"source":"DrugCentral","atcCode":"B02AB01","allCodes":["B02AB01"]},"biosimilarFilings":[],"originalDeveloper":"Bayer Hlthcare","recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"withdrawn","companyName":"Bayer","companyId":"bayer","modality":"Small Molecule","firstApprovalDate":"1993","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:31:15.660874+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}